Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adverse Drug Reactions in Relation to Clozapine Plasma Levels: A Systematic Review
Μαρία Σκώκου, Eleni A. Karavia, Zoi Drakou, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 7, pp. 817-817
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia
Mishal Qubad, Robert A. Bittner
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 17
Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)
Carlos De las Cuevas, Emílio J. Sanz, José de León
Schizophrenia Research (2023)
Open Access | Times Cited: 16
Association Between Clozapine Plasma Concentrations and Treatment Response: A Systematic Review, Meta-analysis and Individual Participant Data Meta-analysis
Federica Tralongo, Céline Konecki, Catherine Féliu, et al.
Clinical Pharmacokinetics (2023) Vol. 62, Iss. 6, pp. 807-818
Closed Access | Times Cited: 13
Optimizing co-prescription of clozapine and antiseizure medications: a systematic review and expert recommendations for clinical practice
Hélène Verdoux, Clélia Quilès, José de León
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 5, pp. 347-358
Closed Access | Times Cited: 5
Effectiveness of accelerated intermittent theta burst stimulation for social cognition and negative symptoms among individuals with schizophrenia: A randomized controlled trial
Ying Jin, Jie Tong, Ying Huang, et al.
Psychiatry Research (2022) Vol. 320, pp. 115033-115033
Open Access | Times Cited: 21
Current Status of Therapeutic Drug Monitoring in Mental Health Treatment: A Review
Filippo Pennazio, Claudio Brasso, Vincenzo Villari, et al.
Pharmaceutics (2022) Vol. 14, Iss. 12, pp. 2674-2674
Open Access | Times Cited: 19
Therapeutic monitoring of plasma clozapine andN-desmethylclozapine (norclozapine): practical considerations
Robert J. Flanagan, Siobhan Gee, Sarah L. Belsey, et al.
BJPsych Advances (2023) Vol. 29, Iss. 2, pp. 92-102
Open Access | Times Cited: 12
Analysis of clozapine-induced seizures using the Japanese Adverse Drug Event Report database
Masakazu Hatano, Kaho Yamada, Haruna Matsuzaki, et al.
PLoS ONE (2023) Vol. 18, Iss. 6, pp. e0287122-e0287122
Open Access | Times Cited: 11
Letter to the editor concerning: Risk of agranulocytosis and neutropenia in patients with Parkinson's disease psychosis receiving clozapine treatment: A systematic review and meta-analysis. Limveeraprajak N, Makkapavee W, Likhitsathian S, Srisurapanont M. Possibly a greater risk?
Joseph H. Friedman
General Hospital Psychiatry (2025) Vol. 93, pp. 80-81
Closed Access
Forensic considerations in cases of fatal constipation
Roger W. Byard, Neil E. I. Langlois, Marianne Tiemensma
Forensic Science Medicine and Pathology (2025)
Open Access
The Impact of Therapeutic Drug Monitoring on Clozapine Dosing and Clinical Outcome in a Tertiary Care Center in India
Lakshmi Jogi, P Praveen, Aromal Shibu, et al.
Journal of Clinical Psychopharmacology (2025)
Closed Access
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I
José de León, Ross J. Baldessarini, Richard Balon, et al.
Journal of Clinical Psychopharmacology (2025)
Closed Access
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II
José de León, Ross J. Baldessarini, Richard Balon, et al.
Journal of Clinical Psychopharmacology (2025)
Closed Access
Plasma Clozapine in Treatment Refractory Schizophrenia
Robert J. Flanagan, Stephen John Obee, Alice Hyun Min Kim, et al.
Journal of Clinical Psychopharmacology (2025)
Closed Access
Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 2016
Lene Bleich, R. Grohmann, W. Greil, et al.
Journal of Neural Transmission (2024) Vol. 131, Iss. 9, pp. 1117-1134
Open Access | Times Cited: 2
Prevalence of clozapine-induced sialorrhea and its effect on quality of life
David Sanagustín, Marta Martín-Subero, Bridget Hogg, et al.
Psychopharmacology (2022) Vol. 240, Iss. 1, pp. 203-211
Closed Access | Times Cited: 9
A systematic chart review of pharmacological interventions in patients with clozapine-induced hypersalivation
Emre Mutlu, Elçin Özçelik Eroğlu, Fehmi Çoşkun, et al.
Schizophrenia Research (2023)
Closed Access | Times Cited: 5
Clozapine—serious adverse effects and clinical management
Vlad Dionisie
Elsevier eBooks (2024), pp. 329-355
Closed Access | Times Cited: 1
The prevalence of constipation in adult psychiatric out‐patients on clozapine treatment at a regional public hospital in Hong Kong
Eric Wai‐Fung Lam, Brian Pak‐In Ip
Human Psychopharmacology Clinical and Experimental (2024) Vol. 39, Iss. 5
Closed Access | Times Cited: 1
Recurrent high creatine kinase levels under clozapine treatment - a case report assessing a suspected adverse drug reaction
Florine M. Wiss, Samuel Allemann, Henriette E. Meyer zu Schwabedissen, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 1
Evidence for Therapeutic Drug Monitoring of Atypical Antipsychotics
Veronika Krejčí, Irena Murínová, Ondřej Slanař, et al.
Prague Medical Report (2024) Vol. 125, Iss. 2, pp. 101-129
Open Access | Times Cited: 1
The Potential Role of POR*28 and CYP1A2*F Genetic Variations and Lifestyle Factors on Clozapine and N-DesmethylClozapine Plasma Levels in Schizophrenia Patients
Merve Demirbügen Öz, F. Özdemir, Kenan Can Tok, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 5, pp. 319-327
Closed Access | Times Cited: 3
Assessing Adherence to Clozapine
Robert J. Flanagan, Samora Hunter, Stephen John Obee
Journal of Clinical Psychopharmacology (2023) Vol. 43, Iss. 5, pp. 417-421
Closed Access | Times Cited: 2
Molecular Mechanisms of Clozapine-Induced Pancreatic Damage and its Modulation by L-Carnitine in a Rat Model
Dalia Mesallam, Eman Ahmed Alaa El-Din, Mai Said Ibrahim, et al.
Egyptian Society of Clinical Toxicology Journal (2024) Vol. 12, Iss. 1, pp. 182-199
Open Access
Clozapine levels and outcomes in Serbian patients with treatment-resistant psychotic disorders previously treated without measuring clozapine levels (CLOSER)
H. Haas, Dan Cohen, Mariken B. de Koning, et al.
Psychiatry Research (2024) Vol. 339, pp. 116070-116070
Open Access
Page 1 - Next Page

Scroll to top